Phase 1, single ascending dose data for the GalNAc-conjugated siRNA apoCIII inhibitor, ION775, support the safety and tolerability of treatment in patients with moderate hypertriglyceridaemia for up to 12 months.
Educational partners and supporters
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
